arrow
S

Surbhi Sidana

Stanford University
H指数:37
被引数:7,080

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

真实世界中接受cilta-cabtagene autoleucel治疗的虚弱患者的疗效与安全性:国际血液与骨髓移植研究中心分析

Cancer
IF5.1
2026-09-250
OAAI
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
2026-08-310
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

真实世界中接受Ciltacabtagene autoleucel治疗的复发或难治性多发性骨髓瘤患者中非ICANS神经事件的大规模美国数据库描述

2026-04-180
OAAI
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

西达基奥仑赛注射液(cilta-cabtagene autoleucel)治疗复发/难治性多发性骨髓瘤的安全性和有效性:一项CIBMTR研究

2026-04-140
OAAI
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy

复发/难治性多发性骨髓瘤患者接受BCMA靶向CAR-T治疗后BCMA表达动力学

2026-04-040
OA
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

elranatamab治疗多发性骨髓瘤的真实世界结局: 来自美国多发性骨髓瘤免疫治疗联盟的多中心分析

2026-03-270
OAAI
Superior Chronic Graft-versus-Host Disease–Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation

与他克莫司/甲氨蝶呤相比,在骨髓清除性HLA匹配的异基因造血细胞移植中,移植后环磷酰胺具有更优的慢性移植物抗宿主病无病生存率

2026-03-250
OAAI
Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS

早期使用糖皮质激素和Anakinra管理Axicabtagene ciloleucel毒性的总CRS和ICANS持续时间减少

2026-03-230
OAAI
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma

系统性AL淀粉样变性伴发骨髓瘤中商业化BCMA靶向CAR T细胞疗法的安全性与有效性

2026-03-200
PREAI
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Cilta-cel 在来那度胺难治性多发性骨髓瘤中的疗效(CARTITUDE-4):一项开放标签、多中心、随机、III期试验的更新分析,包括总生存期数据

2026-01-070
OAAI
Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma

西达基奥仑赛注射液(ciltacabtagene autoleucel)在重度预治疗复发或难治性多发性骨髓瘤患者中引发的细胞减少症和感染

2026-01-014
OA
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort

三线治疗后复发/难治性多发性骨髓瘤中特克替单抗的疗效和安全性:三项临床队列和一项回顾性队列的合并分析结果

Cancer
IF5.1
2026-01-011
OAAI
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Teclistamab联合Daratumumab治疗复发或难治性多发性骨髓瘤

2025-12-015
PRE
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine

胃肠道CAR T细胞淋巴瘤的长期随访:归巢、克隆性增殖及对环孢素的治疗反应

Blood
IF23.1
2025-11-270
PRE
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4

在CARTITUDE-1、-2和-4研究中,接受ciltacabtagene autoleucel输注治疗复发/难治性MM患者的颅神经麻痹临床经验。

2025-11-260
OAAI